In recent years, many new immunosuppressive drugs have been discovered and developed
for clinical use in transplantation. This review focuses on those drugs (leflunomide,
mycophenolate mofetil, sirolimus, tacrolimus) that have been shown to have
immunosuppressive activity in patients. Different anti-interleukin-2 receptor antibodies are
also reviewed as an example of a resurgence of development in the area of monoclonal
antibodies. The price for reducing the incidence of allograft rejection by improved …